<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208753</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0555-CL-102</org_study_id>
    <secondary_id>2010-018570-20</secondary_id>
    <nct_id>NCT01208753</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects</brief_title>
  <official_title>Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of GLPG0555 in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of multiple ascending
      oral doses (MAD) of GLPG0555 given to healthy subjects for 13 days compared to placebo, and
      to evaluate the relative bioavailability and pharmacokinetics (PK) of two different aqueous
      suspensions of GLPG0555 administered for 3 days. Finally, it is aimed to characterize PK and
      pharmacodynamics (PD) of GLPG0555 after multiple oral administrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple dosing</measure>
    <time_frame>Daily during treatment, up to 10 days postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of repeated doses</measure>
    <time_frame>24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of GLPG0555 after repeated oral administration</measure>
    <time_frame>up to 10 days postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative bioavailability and pharmacokinetics (PK) of two different aqueous suspensions administered for three days</measure>
    <time_frame>up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Aqueous formulations for formulation selection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG0555 ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once or twice daily for 13 days, matching the scheme of the multiple ascending dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0555</intervention_name>
    <description>two different aqueous formulations</description>
    <arm_group_label>Aqueous formulations for formulation selection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0555 aqueous</intervention_name>
    <description>multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined</description>
    <arm_group_label>GLPG0555 ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male, age 18-50 years

          -  BMI between 18-30 kg/mÂ², inclusive.

        Exclusion Criteria:

          -  significantly abnormal platelet function or coagulopathy

          -  smoking

          -  drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerben van 't Klooster, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wouter Haazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Senior Vice President Development</name_title>
    <organization>Galapagos NV</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

